HOLD

• Trial narrative is a binary headline event with unknown duration and amplitude requiring position sizing discipline, not dismissal of a seven-week proceeding
• FCF collapsed 81% YoY to $1.75B; buybacks paused; net debt quadrupled to $68B; $24B debt issuance in single quarter signals balance sheet under pressure
• Technical setup shows RSI 37 with MACD histogram at negative 4.21, price below all three moving averages in bearish stack, and VWMA sloping above price—not exhaustion but trend continuation
• July 30 and August 18 distribution days totaled 42M and 27M shares respectively, representing institutional selling, not 'clearing weak hands'
• Forward P/E of 15.7x driven by analyst EPS estimates that face 10-15% downside risk from capex super-cycle, which would push multiple to 19-21x
• Entry at $520 and stop-loss at $519.78 create no real risk-reward asymmetry; directional conviction is masquerading as analysis
• Protective puts near $510 are the centerpiece of risk management for binary trial outcomes and capex surprises that diversification cannot hedge

→ vs aggressive: Calling a $1.4T market cap loss 'rounding error' ignores the seven-week trial's real-time stock impact during proceedings with emotionally devastating testimony

→ vs aggressive: Framing $9B to $1.75B FCF collapse as 'strategic aggression' with 'optional' capex ignores that FCF funds buybacks, dividends, debt service, and reinvestment

→ vs aggressive: Describing RSI 37 as exhaustion ignores MACD at negative 4.21, bearish stacked moving averages, and VWAP above price—all indicating trend continuation, not reversal

→ vs aggressive: Using constructive macro to justify single-name exposure in deteriorating fundamentals contradicts the principle that macro does not insulate idiosyncratic risk

→ vs aggressive: Forward P/E of 15.7x appears cheap only if analyst EPS estimates hold; 10-15% cuts would push multiple to 19-21x, collapsing the valuation thesis

→ vs aggressive: Scaling into a falling knife with entry and invalidation at essentially the same price ($520 vs $519.78) violates risk management principles and offers no real asymmetry

HOLD

• PEG of 0.88 with 28% revenue growth at trillion-dollar market cap is a legitimate valuation observation
• Macro backdrop is constructive with on-hold Fed and recession odds at 8% and falling
• Forward P/E of 15.7 is the actual multiple the market is using to value the stock
• Revenue trajectory accelerated to 28% in Q2, not supporting a permanent earnings downgrade thesis
• Trial creates path-dependent volatility with 5-15% daily moves possible regardless of final outcome; $1.4 trillion damages figure is the procedural risk
• Market is pricing uncertainty about Meta's specific AI capex ROI, not AI spending broadly; 81% FCF collapse with paused buybacks and quadrupling net debt in 12 months is real concern
• RSI at 37 represents both short-term exhaustion and ongoing downtrend continuation simultaneously
• Add zone: $519 to $525 only with RSI below 30, volume climax above 35 million shares, AND narrowed trial damages figure
• Trim zone: reclaim 50 SMA at $594 with rising volume and bullish MACD histogram cross
• Hedge refinement: $510 puts expiring after Q3 2026 earnings reasonable, but $530 or $540 shorter-duration puts may provide similar protection at lower cost
• Position sizing must survive adverse 1-2 ATR moves ($44) without forcing ill-timed decisions
• Waiting for full confirmation and adding into downtrend both have real costs; advance trigger definition provides disciplined middle path

→ vs aggressive: Calling the trial outcome a 'rounding error' is intellectually dishonest; the trial creates 7 weeks of path-dependent volatility where daily headlines can move the stock 5-15% regardless of final damages

→ vs aggressive: Market is specifically concerned about Meta's AI capex ROI, not AI spending broadly; Microsoft, Alphabet, and Amazon face similar capex but haven't seen the same multiple compression as Meta

→ vs conservative: 'Do nothing aggressively' with puts as centerpiece is over-hedging that bakes in defensive posture and underweights genuine opportunity at valid valuations

→ vs conservative: 'Catching a knife' analogy overstates danger; mega-cap tech has repeatedly shown V-bottoms at value levels with constructive macro are not rare events

→ vs conservative: 'Missed bottom is recoverable' underweights the real opportunity cost; a 20% rally on minimal trial damages within 3 months represents meaningful portfolio drag